key: cord-1018134-8hrjl6qd
authors: Zhang, D.; Xu, T.; Chu, E.; Zhang, A.; Du, J.; Sha, M.
title: A High-throughput Microsphere-based Immunoassay of Anti-SARS-CoV-2 IgM Testing for COVID-19 Diagnostics
date: 2021-01-26
journal: nan
DOI: 10.1101/2021.01.22.20249050
sha: 251aa7748dea0c358662584ed016ec13f1c74278
doc_id: 1018134
cord_uid: 8hrjl6qd

The pandemic of novel coronavirus disease COVID-19 is rapidly expanding across the world. A positive result of antibody tests suggests that the individual has potentially been exposed to SARS-CoV-2, thus allowing to identify asymptomatic infections and determine the seroprevalence in a given population. The aim of this study was to evaluate the performances of a newly developed high throughput immunoassay for anti-SARS-CoV-2 IgM antibody detection on the Luminex MAGPIX platform. Clinical agreement studies were performed in 42 COVID-19 patient serum samples and 162 negative donor serum/plasma samples. Positive percent agreement (PPA) was 42.86% (95% CI: 9.90% to 81.59%), 71.43% (95% CI: 29.04% to 96.33%), and 28.57% (95% CI: 13.22% to 48.67%) for samples collected on 0-7 days, 8-14 days, and 2-8 weeks from symptom onset, respectively. Negative Percent Agreement (NPA) was 97.53% (95% CI: 93.80% to 99.32%). There was no cross-reactivity with the SARS-CoV-2 IgG antibody. Hemoglobin (200 mg/dL), bilirubin (2 mg/dL), triglyceride (250 mg/dL) and EDTA (10 mM) showed no significant interfering effect on this assay. In conclusion, an anti-SARS-CoV-2 IgM antibody assay with high sensitivity and specificity has been developed. With the high throughput, this assay will speed up the anti-SARS-CoV-2 IgM testing.

The SARS-CoV-2 virus has been identified as the cause of a respiratory illness outbreak in Wuhan, China in late 2019 and has since evolved into a global pandemic, COVID-19. As of early November 2020, 47 million people have contracted the virus and more than 1 million people have died. Nucleic acid amplification testing methods such as PCR have been the gold standard for COVID-19 detection during the early phase of infection. However, there is an increasing demand for antibody detection for confirm results for clinically suspicious cases, and help guide return-to-work or travelling decisions (5) .

Herein, we reported the performance evaluation of the QuantiVirus™ anti-SARS-CoV-2 IgM test which is a two-step immunoassay using Luminex platform to detect anti-SARS-CoV-2 spike protein 1 (S1) receptor-binding domain (RBD) IgM antibody in human serum or plasma specimens. Validation of the test was conducted using COVID-19 negative and positive samples on MAGPIX ® instruments. The test takes approximately 3 hours per run with a 96-well plate capable of testing 92 patient samples, enabling a streamlined workflow for high-throughput COVID-19 antibody testing.

All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. 

According to the guidance issued by Centers for Disease Control (CDC) and the World Health Organization (WHO), all studies were conducted in a Biosafety Level 2 (BSL-2) cabinet when handling COVID-19 patient samples. The microplate shaker (PlexBio Co, Taiwan) was used for microplate shaking and incubation. Data acquisition was performed on Luminex MAGPIX ® instruments (Luminex, Austin, TX).

The recombinant SARS-CoV-2 Spike protein 1 (RBD)-His was produced from HEK293 suspension cells COVID-19 patient serum samples were acquired from ProMedDx (Norton, MA).

Principle of the assay is shown in Figure 1 . Recombinant spike protein 1 (S1) RBD was covalently coupled to the surface of MagPlex ® Microspheres (magnetic beads) via a carbodiimide linkage using xMAP ® Antibody Coupling (AbC) kit. First, 3 µL of S1 RBD protein coated magnetic beads, 87 µL of BlockAid™ Blocking Solution and 10 µL of serum or plasma samples were loaded to 96-well plate and incubated at room temperature for 1 hour with shaking at 600rpm. The IgM antibodies present in human specimens against S1 RBD protein (the antigen) will bind to the coated magnetic beads. After washing, All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 26, 2021. ; https://doi.org/10.1101/2021.01.22.20249050 doi: medRxiv preprint PE conjugated anti-human IgM antibody was added to the reaction mixture and incubated at room temperature for 30 minutes with shaking at 600rpm. After washing, data acquisition was performed on MAGPIX ® instrument for Median Fluorescence Intensity (MFI). Interpretation of the testing results was performed by calculating the ratio between the MFI of each sample and the average MFI of two blank wells. The sample will be interpreted as positive when the ratio is ≥ 45; otherwise, the sample will be considered negative for Anti-SARS-CoV-2 IgM antibody.

To evaluate the clinical performance of the QuantiVirus TM Anti-SARS-CoV-2 IgM Test, 162 COVID-19 negative samples and 42 COVID-19 positive samples were tested and evaluated for NPA and PPA.

Class specificity was evaluated by testing ten IgG-positive and IgM-negative patient samples. Within-run precision (repeatability) was evaluated by testing negative sample and positive sample in 20 replicates.

Between-run precision was evaluated by testing negative sample and positive sample on five separate runs with two replicates per run. For interference testing, hemoglobin (200 mg/dL), bilirubin (2 mg/dL), triglyceride (250 mg/dL) and EDTA (10mM) were spiked into serum samples, respectively, and the MFI was compared with the control samples.

For precision evaluations, coefficient of variation (CV) was calculated as the ratio of the standard deviation (SD) to the mean. For interference testing, the samples spiked with potential interfering substances were compared with the control samples by paired T-test with p≤0.05 defined as significantly different.

Forty two (42) serum samples collected at different times from individuals who tested positive with a RT-PCR method for SARS-CoV-2 infection were used in the evaluation of positive percent agreement (PPA).

One hundred and sixty two (162) serum or EDTA plasma samples collected from healthy donors were All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. In addition, 4 pairs of matched serum and EDTA plasma samples (i.e. collected from the same COVID-19 patients) were tested with QuantiVirus TM Anti-SARS-CoV-2 IgM Test and 100% concordance was observed (data not shown). It indicates that EDTA plasma is as acceptable as serum for this test.

Hemoglobin (200 mg/dL) was spiked into three serum samples to test the potential interfering effect of high-level hemoglobin which might be present in hemolysis and other conditions. Bilirubin (2 mg/dL) was spiked into three serum samples to test the potential interfering effect of high-level bilirubin in the blood which might be caused by liver dysfunction such as hepatitis and cirrhosis. Triglyceride (250 mg/dL) was spiked into three serum samples to test the potential interfering effect of high triglyceride levels which are often a sign of conditions that increase the risk of heart disease and stroke, including obesity and metabolic syndrome. Lastly, EDTA (10mM) was spiked into three serum samples to test the potential interfering effect of EDTA which is the anticoagulant used in EDTA blood collection tubes.

As shown in Table 2 , the difference in the fluorescence signal (MFI) between the control samples and the samples spiked with hemoglobin, bilirubin, triglyceride or EDTA was all ≤ 15.0% which is acceptable to the test and no false negative or false positive results were observed.

Intra-assay reproducibility (repeatability) was evaluated by testing negative sample and positive sample in 20 replicates and the CV% of MFI was calculated. Inter-assay reproducibility (between-run precision) was evaluated by testing negative sample and positive sample on five separate runs and the CV% of the All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Ratio of MFI Sample to MFI Blank was calculated. As shown in Table 3 and Table 4 , the CV% of within-run precision and between-run precision was below 15.0% and 20.0%, respectively.

Antibody class specificity between IgM and IgG was tested for cross reactivity. Ten SARS-CoV-2 patient samples which were positive for IgG and negative for IgM (tested by DIAZYME SARS-CoV-2 IgG and

IgM CLIA kit) were tested with QuantiVirus™ anti-SARS-CoV-2 IgM test and all were negative, thus establishing the specificity of the QuantiVirus™ anti-SARS-CoV-2 IgM test to the IgM class of antibodies (Table 5 ).

Antibody tests are blood tests that detect antibodies or immunoglobulins that are produced as the human immune response to SARS-CoV-2 infection. Antibody testing has multiple essential roles: it can identify asymptomatic infections, verify that vaccines are working, be used in contact tracing after a suspected infection in an individual, and to help inform public policy makers how many asymptomatic cases have occurred in a population (6) (7) (8) . As of October 28, 2020, more than 50 serological tests have been approved by FDA for emergency use authorization (EUA) for the detection of anti-SARS-CoV-2 IgM, IgG, or total antibodies and in various formats including lateral flow immunoassays (LFAs), enzymelinked immunosorbent assays (ELISAs), chemiluminescent immunoassays (CLIA), and beads-based fluorescent immunoassays (9).

Despite the enormous efforts put by companies and researchers into developing serological assays, diagnostic accuracy of serological tests for COVID-19 has been largely variable. Bastos et al performed a systematic review and meta-analysis of published data on Medline, bioRxiv, and medRxiv from 1 January to 30 April 2020, and found that the pooled sensitivity of ELISAs measuring IgG or IgM was 84.3% (95% confidence interval 75.6% to 90.9%), of LFIAs was 66.0% (49.3% to 79.3%), and of CLIAs was 97.8% (46.2% to 100%) (10) . Furthermore, sensitivity was higher at least three weeks after symptom onset All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 26, 2021. ; https://doi.org/10.1101/2021.01.22.20249050 doi: medRxiv preprint (ranging from 69.9% to 98.9%) compared with within the first week (from 13.4% to 50.3%). Similar findings have been confirmed by other investigators as well (11, 12) .

Of note, multiple publications have indicated that the appearance of detectable anti-SARS-CoV-2 IgM antibodies after infection with COVID-19 is delayed, resulting in abnormal sensitivity in the early days after the onset of symptoms. For instance, a group from Germany observed that less than 50% of patients produced detectable anti-SARS-COV-2 IgM in the first 10 to 14 days after the "onset" of symptoms (13) .

Similarly, Long et al showed that only 12% to 40% of patients developed anti-SARS-COV-2 IgM seroconversion during 1 to 7 days post onset of symptom (14). Using an ELISA designed to detect anti-SARS-COV-2 IgM antibodies against the RBD of the S1 subunit, data from Zhao et al. showed that approximately 28% of patients were IgM positive by day 7 whereas 73% turned positive by day 14 post symptom onset (15). In agreement with those previous findings, using the QuantiVirus TM anti-SARS-CoV-2 IgM Test developed in our lab, we found that 42.86% of patients produced detectable IgM antibody in the first 7 days post symptom onset and increased to 71.43% by day 14. The test indicated a leading accuracy of report for the patient samples in the first 7 days, and a reliable report rate as the time extended.

To further establish the assay accuracy, and consistency against various patient conditions, we also showed that this microsphere -based fluorescence immunoassay has a high specificity of 97.53% and is compatible with both serum and EDTA-plasma samples. The interference of substances, such as hemoglobin, bilirubin and triglyceride, would not generate inaccurate results. This indicates the potential application of our test on patients with certain health conditions. QuantiVirus TM anti-SARS-CoV-2 IgM Test also demonstrated an excellent reproducibility, where the intra-assay variations are lower than 15% for positive samples, and 6.4% for the negative serum sample.

The variations are below 20% when it comes to the comparison of readings among 5 different test runs.

Therefore, QuantiVirus TM anti-SARS-CoV-2 IgM Test provides reliable, reproducible results for patient screening, confirmation, and tracing. All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. In addition, QuantiVirus TM anti-SARS-CoV-2 IgM Test provides a simplified workflow for clinical practices (Figure 1 ). The pre-coupled capture beads and reporting complex reduced the time-consuming operations of RBD binding. Reducing the workflow could further reduce the operational error introduced from RBD protein conjugation. The workflow can be quickly adapted by clinical practices to improve the throughput and can be easily integrated into a laboratory's clinical operations.

In conclusion, we have successfully developed a reliable high-throughput microsphere immunoassay for qualitative detection of anti-SARS-CoV-2 IgM antibody. The assay was validated with COVID19 positive samples as well as negative samples obtained from healthy donors on MAGPIX ® instrument. We believe that this assay will help to determine the infection status of COVID-19 and the true scope of the pandemic. All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 26, 2021. ; https://doi.org/10.1101/2021.01.22.20249050 doi: medRxiv preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 26, 2021. ; https://doi.org/10.1101/2021.01.22.20249050 doi: medRxiv preprint

A Novel Coronavirus from Patients with Pneumonia in China

First Case of 2019 Novel Coronavirus in the United States

No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity

Laboratory diagnosis of emerging human coronavirus infections -the state of the art

Antibody responses to SARS-CoV-2 in patients with COVID-19

Report from the American Society for Microbiology COVID-19 International Summit

Antibody Testing for COVID-19

The Role of Antibody Testing for SARS-CoV-2: Is There One?

Developing antibody tests for SARS-CoV-2

Diagnostic accuracy of serological tests for covid-19: systematic review and meta-analysis

Antibody Tests in Detecting SARS-CoV-2 Infection: A Meta-Analysis

Meta-analysis of diagnostic performance of serology tests for COVID-19: impact of assay design and post-symptom-onset intervals

Virological assessment of hospitalized patients with COVID-2019